Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Financial results Q4 - FY 202423-05-2024
23-05-2024
Strides Pharma Science Ltd - 532531 - Intimation Regarding Receipt Of Observation Letters From BSE Limited And The National Stock Exchange Of India Limited In Relation To The Proposed Scheme Of Arrangement Amongst Strides Pharma Science Limited (Strides/ Company) And Steriscience Specialties Private Limited (SSPL) And Stelis Biopharma Limited (SBL) And Their Respective Shareholders ('Draft Scheme') Pursuant To Section 230 To 232 Read With Other Applicable Provisions Of The Companies Act, 2013.
Intimation regarding receipt of Observation Letters from BSE & NSE22-05-2024
Strides Pharma Reports Profit In Q4; USFDA Approves Generic Gastrointestinal Drug
Strides Pharma reports Rs 10.44 crore net profit in Q4; USFDA approves generic gastrointestinal drug22-05-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings Call - Audio link22-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for Strides Pharma Science Ltd.
Pharmaceuticals company Strides Pharma Science announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Highest ever quarterly Revenue of Rs 10,583 million Gross Margin returned to a historic high of 60.7% in Q4FY24 Highest ever quarterly EBITDA of Rs 2,040 million FY24 Financial Highlights: Highest ever full-year Revenue of Rs 40,555 million in FY24, up 14.4% YoY Highest ever full-year EBITDA of Rs 7,477 million in FY24, up 77.6% YoY US business achieved top end of USD 250 million revenue outlook for FY24, grew by 11.8% YoY Net Debt reduced by Rs 3,131 million in FY24 Net Debt to EBITDA improved to 2.72x in FY24 Arun Kumar, Founder, Executive Chairperson & Managing Director, commented on the performance and said, “FY24 was an exceptional year for Strides, marked by the successful completion of our Reset strategy initiated in FY22. The company achieved all its key objectives laid down in our Reset strategy and has bounced back to become a strong and resilient company. As a result of our focus on consistent growth and cost containment, FY24 concluded as the best year in the Company’s history in terms of both Revenue and absolute EBITDA. With today’s leadership announcement, we have introduced a well-structured succession and leadership development program, guided by the Board. I am confident that the strong internal talent we have developed over the years will ensure the company's continued long-term growth. In the near term, we will continue to focus on operating cash flows while investing in growth to ensure that the efforts of our Reset are balanced by an improved revenue CAGR, in the coming years. Our ESG efforts have started to yield results, with our EcoVadis rating improving from 30 to 44 during the first year of review. We will continue to intensify our efforts to become a more sustainable and responsible company”. Result PDF22-05-2024
Strides Pharma Science Ltd - 532531 - Disposal Of Corporate Insolvency Process Against Strides Alathur Private Limited (Formerly Vivimed Life Sciences Private Limited)
Disposal of Corporate Insolvency Process against Strides Alathur Private Limited (formerly Vivimed Life Science Private Limited)22-05-2024
Strides Pharma Science Ltd - 532531 - Grant Of Stock Options Under Strides ESOP Plan
Grant of Stock Options under Strides ESOP Plan22-05-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Shares22-05-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Management
Outcome of Board Meeting - May 22, 2024 - Change in Management22-05-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Directorate
Outcome of Board Meeting - May 22, 2024 - Change in Board composition and Management22-05-2024